RSR13 FDA Approval Status

FDA Approved: No
Brand name: RSR13
Generic name: efaproxiral
Company: Allos Therapeutics, Inc.
Treatment for: Brain Metastases in patients with Breast Cancer

Development timeline for RSR13

Date	Article
Jun 16, 2004	Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe
Jun 2, 2004	Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral)
May 4, 2004	FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases Originating From Breast Cancer
Mar 12, 2004	Allos NDA To Be Reviewed By FDA Advisory Committee
Feb 3, 2004	FDA Accepts Allos New Drug Application with Priority Review for RSR13 in Brain Metastases from Breast Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer